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ABSTRACT
Glucagon-like peptide-1 (GLP-1) receptor
agonists (GLP-1 RAs) are useful tools for
treating type 2 diabetes mellitus. In their
recent position statement, the American
Diabetes Association and European Association
for the Study of Diabetes recommend GLP1-RAs
as add-on to metformin when therapeutic goals
are not achieved with monotherapy,
particularly for patients who wish to avoid
weight gain or hypoglycemia. GLP1-RAs differ
substantially in their duration of action,
frequency of administration and clinical
profile. Members of this class approved for
clinical use include exenatide twice-daily,
exenatide once-weekly, liraglutide and
lixisenatide once-daily. Recently, two new
once-weekly GLP1-RAs have been approved:
dulaglutide and albiglutide. This article
summarizes properties of short- and
long-acting GLP-1 analogs, and provides useful
information to help choose the most
appropriate compound for individual patients.
Keywords: Glucagon-like peptide-1 receptor
agonists; GLP-1 RAs; Incretin; Type 2 diabetes
mellitus
INTRODUCTION
Glucagon-like peptide-1 (GLP-1) receptor
agonists (GLP-1 RAs) are useful tools for
treating type 2 diabetes mellitus (T2DM). In
their recent position statement, the American
Diabetes Association and European Association
for the Study of Diabetes recommend GLP1-RAs
as add-on to metformin when therapeutic goals
are not achieved with monotherapy,
particularly for patients who wish to avoid
Electronic supplementary material The online
version of this article (doi:10.1007/s13300-015-0127-x)
contains supplementary material, which is available to
authorized users.
A. Uccellatore (&)
University of Milan, Milan, Italy
e-mail: annachiara.uccellatore@multimedica.it
S. Genovese
Diabetes Endocrine and Metabolic Diseases Unit,
IRCCS MultiMedica, 20099 Sesto San Giovanni,
MI, Italy
I. Dicembrini  E. Mannucci
Diabetes Agency, Careggi Hospital, Florence, Italy
A. Ceriello
Insititut d’Investigacions Biome`diques August Pi
Sunyer, Hospital Clinic, Barcelona, Spain
Diabetes Ther (2015) 6:239–256
DOI 10.1007/s13300-015-0127-x
weight gain or hypoglycemia [1]. This article
summarizes properties of short- and long-acting
GLP-1 analogs, providing useful information for
choosing the most appropriate compound for
individual patients.
METHODS
The present paper is based on a review of recent
publications on GLP-1 RA therapy and data
from controlled clinical trials undertaken to
investigate properties, functions, efficacy and
safety of GLP RAs. Searches of PubMed were
conducted for articles published between
December 2013 and July 2014 using the terms
‘‘GLP-1 receptor agonist therapy’’, ‘‘GLP-1 and
extraglycemic effects’’, ‘‘lixisenatide’’,
‘‘exenatide’’, ‘‘liraglutide’’, ‘‘dulaglutide’’,
‘‘albiglutide’’, and ‘‘long-acting GLP-1 RA’’.
For the introduction, we considered articles
published between 1996 and 2013 on the
biology and physiology of the incretin
hormones and their role in the
pathophysiology of T2DM. We focused on
recent reviews on GLP-1 RA, meta-analyses
and controlled clinical trials (January 2005 to
October 2014). In particular, we analyzed
controlled clinical trials comparing short- and
long-acting GLP-1 RA, GLP-1 RA versus insulin,
and GLP-1 versus oral agents. We also examined
two meta-analyses: one around the efficacy and
safety of incretin therapy, and the other
comparing exenatide once-weekly or
liraglutide once-daily with insulin glargine,
exenatide twice-daily or placebo.
Our goal was to analyze the therapies for
diabetes in use today and emphasize the
mechanism and clinical efficacy of GLP-1 RA
therapy. We analyze the molecules which are
actually approved by Food Drug Administration
(FDA) and European Medicines Agency (EMA).
This article is based on previously conducted
studies and does not involve any new studies of




The incretin notion is based on the observation
that the insulin response from ingested glucose
is larger and more sustained than that from
intravenously administered glucose, suggesting
that substances produced in the gastrointestinal
tract in response to meals (‘‘incretins’’) stimulate
insulin release [2, 3]. Two incretins have been
identified: gastric inhibitory polypeptide (GIP),
which is secreted by enteroendocrine K-cells in
the proximal gut, and glucagon-like peptide-1
(GLP-1), which is secreted mainly by L-cells
located in the distal ileum. Within minutes of
eating, the active forms of GIP and GLP-1 are
released into the circulation and act by binding
and activating specific G-protein coupled
receptors expressed on b-cells and other
targets, which rapidly increases exocytosis of
insulin granules. Both GIP and GLP-1 are then
rapidly inactivated by the ubiquitous serine
protease dipeptidyl peptidase-4 (DPP-4).
Long-term effects include stimulation of
insulin synthesis [4], an increase in b-cell
proliferation and a reduction in apoptosis [5].
GLP-1 also improves the glycemic profile by
inhibiting glucagon secretion, delaying gastric
emptying, and reducing food intake. GLP-1 may
also improve glucose disposal in peripheral
tissues (Fig. 1) [6–9]. GLP-1 may have an affect
on tissues that are not directly involved in
glucose metabolism, including protection
against myocardial ischemia or reperfusion
injury [10, 11]. In blood vessels, it protects
against endothelial dysfunction [12], and
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promotes endothelium-independent artery
relaxation [13]. It may have renal protective
effects through increases in diuresis and
natriuresis [14, 15]. These actions may lower
blood pressure and have favorable effects on
markers of cardiovascular risk, including brain




In subjects with normal glucose tolerance, the
incretin effect accounts for about two-thirds of
the insulin response to an oral load, whereas in
patients with T2DM this value is less than 20%
[3, 17]. Thus, the incretin response may be
particularly important during the postprandial
period and impaired response may lead to
postprandial hyperglycemia.
The hypothesis that meal-induced GLP-1
secretion is impaired in patients with T2DM
versus control subjects is controversial. A large
cross-sectional study by Toft-Nielsen et al. [18]
showed that meal-induced GLP-1 responses
were significantly reduced in patients with
T2DM; however, in other studies they were
similar to those in healthy participants (Fig. 2),
and were not significantly different in a
meta-analysis of 189 patients with T2DM and
217 healthy controls [19].
A study performed under
hyperinsulinemic–euglycemic clamp
conditions, to maintain the same glucose and
insulin levels in diabetic patients and matched
control subjects, showed that GLP-1 response to
oral glucose was reduced in patients with T2DM
[20]. Because high glucose levels are known to
induce DPP-4 expression [21], it has been
hypothesized that chronic hyperglycemia may
increase GLP-1 clearance, causing lower levels of
circulating active GLP-1 [22]. However, no
reduction in elimination rates of GLP-1 has
been observed in patients with T2DM and
mild-to-moderate hyperglycemia [23]. Thus,
there appears to be some variation in GLP-1
secretion and/or inactivation, and in some
cohorts the GLP-1 response was somewhat
reduced, whereas in other studies such
differences were not as apparent (Fig. 2) [19].
Impairment of the GLP-1 axis could be the
consequence, rather than the cause, of
hyperglycemia, establishing a vicious cycle
that contributes to the maintenance of
elevated glucose levels in T2DM, rather than
to the pathogenesis of the disease.
Fig. 1 Physiology of GLP-1 secretion and action on
GLP-1 receptors in different organs and tissues. GLP-1 is
produced postprandially by intestinal L-cells. Through
activation of insulin receptors on b-cells GLP-1 (like GIP)
stimulates insulin biosynthesis and secretion and inhibits
glucagon secretion in the pancreas, which in turn reduces
hepatic gluconeogenesis. GLP-1 release also exerts protec-
tive effects on the heart and brain. Insulin sensitivity in the
periphery is increased by improved insulin signaling and
reduced gluconeogenesis. GI gastrointestinal, GIP gastric
inhibitory polypeptide, GLP-1 glucagon-like peptide-1.
Modiﬁed with permission from Pratley and Gilbert [106]
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INCRETIN-BASED THERAPIES
Twenty-seven years after the first publication by
Nauck in Diabetologia [17], our understanding of
the role of incretins in the pathophysiology of
T2DM has made great advances [22]. We now
recognize that, although both GIP and GLP-1
stimulate insulin secretion in response to
glycemic excursions, GLP-1 also influences
gastric emptying, satiety and glucagon
secretion [24].
Native GLP-1 has not advanced as a
therapeutic agent because of its rapid
degradation by DPP-4 [25]. The therapeutic
potential of GLP-1 has been realized using two
pharmacologic approaches; first, mimicking
and focusing on GLP-1 via GLP-1 receptor
agonists; and second, inhibiting the action of
DPP-4 via DPP-4 inhibitors [26, 27].
A relevant difference between the
DPP-4-resistant GLP-1 RAs and DPP-4
inhibitors is the route of administration:
GLP-1 RAs require subcutaneous injection,
whereas all DPP-4 inhibitors are oral agents,
which may be preferred by patients. However,
subcutaneous injection of GLP-1 RAs stimulates
insulin secretion more strongly than oral
ingestion of DPP-4 inhibitors [28]. This
difference is also due to the fact that, although
DPP-4 inhibition results in supra-physiological
levels of endogenous GLP-1, GLP-1 RAs provide
pharmacological levels of stimulation and more
glucose-lowering efficacy [6, 24, 28]. Data from
animal studies suggest that the effects of
systemic versus local intestinal inhibition of
DPP-4 activity may be different [29]. DPP-4
inhibition may influence glycemia by activating
incretin receptors, preventing the release of
bioactive peptides and affecting
parasympathetic control of the digestive tract
[29]. In addition, unlike DPP-4 inhibitors, GLP-1
RAs slow gastric emptying, increase satiety and
promoting weight loss [6, 24, 28]. The
difference may be explained by the effect of
DPP-4 inhibitors on the degradation of GIP and
neuropeptide Y, which have opposing effects on
gastric motility and satiety [24].
The extraglycemic effects of incretin-based
treatments are also promising. b-cell function is
improved during treatment with incretin
agents, and pre-clinical models show beneficial
effects on b-cell regeneration and function. The
positive effects of incretins on b-cells may
explain, at least partly, the remission of
diabetes documented in obese patients
undergoing some types of bariatric surgery.
Different bariatric surgery procedures result in







































































































































































Fig. 2 Responses of ‘‘total’’ GLP to oral glucose or mixed
meals in patients with T2DM and control subjects.
Integrated responses of ‘‘total’’ GLP to oral glucose or
mixed meals based on individual studies reporting inte-
grated incremental ‘‘total’’ GLP-1 responses in patients
with T2DM and an appropriate control group (weight--
matched, non-diabetic participants) and using non-speciﬁc
assays that measured intact and DPP-4-degraded forms of
GLP-1. The response in patients with T2DM
(mean ± SEM) is expressed as percentage of the mean
value in the control group. *P\0.05 versus control. The
numbers in bars indicate the number of patients with
T2DM (upper row) and control participants (lower row)
studied. Light blue oral glucose, dark blue mixed meal.
DPP-4 dipeptidyl peptidase-4, GLP glucagon-like peptide,
T2DM type 2 diabetes mellitus, SEM standard error of
mean. Modiﬁed with permission from Nauck et al. [19]
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axis with different responses in terms of gut
hormone levels and remission of diabetes. The
ability of GLP-1 to enhance postprandial insulin
secretion in patients who have undergone
Roux-en-Y bypass surgery may also result in
the hyperinsulinemic hypoglycemia
experienced by some patients [30].
The potential cardiovascular benefits of
incretins have attracted much attention.
Reduction of blood pressure, improvement
in lipid profile and endothelial/myocardial
function have been documented in several
pre-clinical and clinical studies, supporting
potential beneficial effects on cardiovascular
outcomes [31]. Data from animal models
suggest that the cardioprotective and
vasodilatory effects of GLP-1 are
independent of the cyclic adenosine
monophosphate (cAMP)-linked GLP-1
receptor and are likely mediated by the
GLP-1 (9–36) metabolite [32].
Lønborg et al. showed that exenatide had a
positive effect on myocardial salvage at the time
of reperfusion in patients with ST-segment
elevation myocardial infarction treated with
primary percutaneous coronary intervention
[33]. The mechanism of exenatide-mediated
protection against reperfusion injury is yet to
be fully clarified. Two key phenomena in
reperfusion injury appear to be the loss of
mitochondrial integrity [34] and myocyte
hypercontracture associated with sarcolemmal
rupture [35]. A large body of experimental
research suggests that reperfusion injury may
be ameliorated by activation of a
receptor-mediated survival pathway [36]. This
pathway is a target for GLP-1-mediated
cardioprotection through activation of
phosphoinositide-3-kinase [10]. However,
other possible targets for exenatide have been
identified, including increased glucose uptake,
inhibition of apoptotic factors, and activation
of cAMP and cyclic guanosine monophosphate
(cGMP). Thus, the cardioprotective action of
GLP-1 receptor stimulation may occur through
a number of pathways encompassing effects on
metabolism, contractility and apoptosis. Other
studies have shown that subcutaneous
exenatide protects
ischemia–reperfusion-induced endothelial
dysfunction through the opening of adenosine
triphosphate-sensitive potassium channels
(KATP channels) [37]. Ischemia–reperfusion
impairs endothelium-dependent vaso-
dilatation; however, pre-treatment with
exenatide protects the endothelium from this
injury [37]. The endothelial protective effect of
exenatide is almost completely prevented when
a KATP channel blocker is administered before
exenatide, suggesting that this effect of GLP-1
RA is mediated by KATP channel opening.
Overall, the available results suggest that
GLP-1 and its receptor agonists exert ischemic
preconditioning through a nitric oxide
(NO)-dependent pathway, of which KATP
channels are key effectors. These findings
represent the first set of evidence in human
subjects for the effects of exenatide on
pharmacological endothelial preconditioning,
and provide a mechanistic explanation for this
phenomenon. Additional studies are needed to
investigate the mechanisms and their potential
clinical implications in greater detail [37].
GLP-1 receptors are widely expressed in the
central nervous system (CNS) where they are
generally associated with the regulation of
appetite and satiety; however, data from
pre-clinical models of Alzheimer’s disease
suggest that GLP-1 may have neurotrophic
and neuroprotective actions, and reduce
amyloid-beta accumulation, thus encouraging
the successful translation of these data into new
treatments for patients with neurodegenerative
CNS disorders [38].
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SHORT-ACTING GLP-1 RAS
Exenatide
Exenatide was the first incretin agent to be
approved for glycemic control in diabetes. The
sequence of this 39-amino acid synthetic
peptide is based on exendin-4 from the lizard
Heloderma suspectum (Gila monster), sharing
53% homology with human GLP-1 [39]. It
binds to the pancreatic GLP-1 receptor and has
many of the glucoregulatory properties of
human GLP-1 [40], with a substantially longer
plasma half-life than GLP-1 due to the presence
of an N-terminal serine in exendin-4 instead of
alanine [41]. The 5–10 lg dose is administered
by subcutaneous injection twice-daily within
1 h of eating a main meal.
Exenatide shares some of the glucoregulatory
effects of GLP-1, but is resistant to DPP-4
degradation. It has a number of actions,
including enhancing glucose-dependent
insulin secretion [42], suppressing postprandial
glucagon secretion, slowing gastric emptying
[43], and reducing caloric intake [44].
Pre-clinical studies have shown that exenatide
also increases pancreatic b-cell mass and clinical
studies have shown that it improves b-cell
function [45, 46]. The efficacy and safety of
exenatide administered in patients with T2DM
not adequately controlled with oral agents (i.e.,
metformin, sulfonylurea, or sulfonylurea plus
metformin) has been demonstrated in a series of
30-week clinical studies [47–49]. In these
studies, up to 46% of exenatide-treated
patients achieved target goals for hemoglobin
A1c (HbA1c) B7% as prescribed by the American
Diabetes Association (ADA) guidelines,
compared with up to 13% of placebo-treated
patients [50]. Mean change from baseline in
body weight in these trials was greater in
exenatide-treated patients (-1.6 to -2.8 kg)
compared to placebo-treated subjects (-0.3 to
-0.9 kg) [47–49].
The efficacy of exenatide as adjunctive
treatment in patients with T2DM receiving
thiazolidinedione was evaluated in a
randomized, double-blind, placebo-controlled
trial [51]. After 16 weeks of treatment, patients
treated with exenatide showed significant
improvements in glycated hemoglobin
(HbA1c), fasting plasma glucose (FPG), and
homeostasis model assessment of b-cell
function (HOMA-B), and promoted weight loss
compared with placebo [51–55]. Exenatide also
improved daily mean postprandial glucose
concentrations (PPG) (based on self-monitored
blood glucose). The incidence of
mild-to-moderate hypoglycemia was similar in
both groups with no severe hypoglycemia
reported [51].
Long-term data describing the effects of
exenatide in the treatment of patients with
T2DM have also been reported [52, 56]. Patients
enrolled in phase III clinical trials have
completed open-label extensions of up to
3.5 years. In addition to exenatide, patients
were also receiving metformin, sulfonylurea,
or a combination of the two therapies, as well as
other agents that reduce cardiovascular (CV)
risk. At baseline, 41% were receiving
angiotensin-converting enzyme inhibitors,
38% were receiving 3-hydroxy-3
methylglutaryl coenzyme A reductase
inhibitors (‘‘statins’’), and 39% were receiving
aspirin. At the end of either 3 years or 3.5 years
of treatment and follow-up, patients showed
significant reductions in HbA1c, FPG, and body
weight from baseline [52]. In the 3-year
completer group, 46% of patients achieved
HbA1c of B7% and 30% achieved HbA1c of
B6.5%. At the 82-week interim analysis, 81% of
patients had lost weight [56]. In general, after
3 years of exenatide, overweight/obese patients
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with greater body mass index (BMI) at baseline
lost more weight, with 84% of patients losing
weight and 50% of patients losing at least 5% of
their body weight. Improvements in HbA1c,
FPG, and body weight with exenatide were
observed regardless of age and were sustained
through 3.5 years of treatment [52]. Over the 3
to 3.5 years of follow-up, patients treated with
exenatide, which was generally well tolerated,
experienced favorable effects on hepatic injury
biomarkers and CV risk factors.
Exenatide-treated patients with elevated
alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) at baseline significantly
improved at 3 years (P\0.001), while patients
with normal ALT and AST values at baseline had
little or no change. In the 3.5-year completer
group, triglycerides, total cholesterol,
low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol, and
systolic and diastolic blood pressure all
showed significant improvements relative to
baseline. The most frequently reported adverse
events (AEs) over the course of the study were
mild-to-moderate nausea (59%) and
hypoglycemia (40%) [52].Generally, the
incidence of nausea was highest during the
first few weeks of treatment, and a significant
reduction was reported after this initial period
[52, 56]. A single event of severe hypoglycemia
occurred in 1 patient who was taking
concomitant metformin and sulfonylurea [52].
A review of current clinical data shows the
estimated incidence of acute pancreatitis related
to any drug therapy is approximately 0.1% to
2% [57]. Acute pancreatitis has been reported in
patients treated with GLP-1 receptor agonist
therapy, although no causal relation has been
found. A retrospective, cohort study found that
patients with T2DM (N = 337,067) may have
nearly a threefold greater risk of acute
pancreatitis compared with patients without
diabetes (N = 337,067) [58]. During the clinical
development of exenatide, the incidence of
acute pancreatitis in exenatide-treated patients
was lower than that observed in patients
receiving insulin or placebo [59]. A recent
claims-based active drug safety surveillance
system revealed that the risk of acute
pancreatitis in patients treated with exenatide
or sitagliptin (relative risk: 1.0 for either agent)
was comparable to that of patients treated with
metformin or glyburide [60]. In addition, post
hoc analyses of serious adverse events reported
in clinical trials have not found an increased
risk of pancreatitis with GLP-1 receptor agonists
[61]. Although postmarketing surveillance data
with exenatide are not sufficient to definitively
establish drug-related causality [59, 60],
exenatide therapy should be stopped in
patients who exhibit symptoms of acute
pancreatitis.
Exenatide was compared with the insulin
analogs biphasic insulin aspart 70/30 (BIAsp
30) [62] and insulin glargine [63]. Results from
these trials suggest that exenatide was not
inferior to insulin therapy in terms of HbA1c
reduction, and may provide better
postprandial glycemic control together with
body weight decrease [64]. It has been
suggested that the insulin dosages
administered in these studies may not have
been optimal [65]. The mean daily dose in the
study comparing exenatide to BIAsp 30 [62]
was 24.4 units, which reduced the mean HbA1c
level by 1.0%. Meanwhile in the INITIATE
study [66], the daily dose was threefold
higher (78.5 units) and this provided a 2.8%
reduction in HbA1c. The daily dose in the study
comparing exenatide to insulin glargine [63]
was 25 units compared to 47 units in the
treat-to-target trial [67]. Thus, it remains to be
determined how exenatide compares with
optimal insulin dosing [68].
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From studies mentioned above, exenatide
treatment was not inferior to insulin in HbA1c
reduction and provided better control of PPG,
making it a potential alternative treatment for
T2DM.
Lixisenatide
Lixisenatide is a selective GLP-1 receptor agonist
with once-daily administration that was
approved in Europe in 2013 for the treatment
of T2DM [69–72]. Data from phase II/III studies
reveal that lixisenatide 20 lg significantly lowers
HbA1c and reduces postprandial hyperglycemia.
Two-hour postprandial glucose excursions were
reduced by approximately 5 mmol/l compared
to placebo after a standard meal [73].
Once-daily lixisenatide was significantly
better at controlling PPG after a standard solid
breakfast compared with liraglutide in a 28-day
clinical trial [74], confirming previous findings
[69, 72, 75]. Compared with liraglutide,
lixisenatide was also significantly better at
reducing postprandial levels of insulin,
C-peptide and glucagon. Whereas both
lixisenatide and liraglutide lowered HbA1c and
body weight over the course of the 28-day
study, differences in their efficacy over the
course of the day were apparent, and there
was also a possible difference in their
pharmacokinetic profiles [69, 76]. Lixisenatide
was better at controlling morning glycemia,




Liraglutide is a human GLP-1 analog in which
lysine 34 is substituted with arginine, and lysine
26 has a C16 acyl chain attached [77]. These
modifications improve the absorption and
extend the half-life compared to native GLP-1,
allowing once-daily administration. After
subcutaneous administration, maximum
concentrations are achieved in 9–14 h, and
half-life is 13 h [78, 79]. Reductions in HbA1c
ranged from 0.6% to 1.6% in clinical trials of
liraglutide administered once-daily at 0.6 to
1.8 mg, alone or in combination with other
agents [80–84].
The 26-week LEAD-6 trial (effect of
liraglutide or exenatide added to an ongoing
treatment on blood glucose control in subjects
with type 2 diabetes) compared once daily
liraglutide 1.8 mg to twice daily exenatide
10 lg in patients with T2DM inadequately
controlled with metformin, a sulfonylurea, or
both. In this trial liraglutide was associated with
significantly greater reductions in mean HbA1c
(-1.1% vs. -0.8%) and fasting plasma glucose
(-29 vs. -11 mg/dL) (P\0.0001 for both) [85].
In a 14-week extension of this trial, patients
who had switched to liraglutide had additional
reductions in mean fasting glucose, as well as
HbA1c (from 7.2% at week 26 to 6.9% at week
40), whereas patients who continued to receive
liraglutide maintained the HbA1c reductions
achieved in the 26-week trial [85]. In other
trials, reductions in FPG with liraglutide ranged
from 13 to 43 mg/dL [80–84]. In the LEAD-6
trial, liraglutide had a greater effect on fasting
glucose, while exenatide was more effective on
PPG [85]. As with exenatide, liraglutide is
associated with dose-dependent weight loss,
ranging from 1.0 to 3.2 kg in clinical trials [80,
82–85], including those examining treatment
regimens combining liraglutide with a
sulfonylurea, which when given as
monotherapy is associated with weight gain
[83]. Patients whose BMI exceeded 35 kg/m2
derived the greatest absolute benefit (weight
loss up to -4.4 kg). Reductions in systolic blood
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pressure with liraglutide 0.6–1.8 mg ranged
from 0.6 to 6.7 mmHg [80–84]. In the LEAD-6
extension trial, switched patients experienced
further reductions in systolic blood pressure
(-2.2 ± 0.88 mmHg; P = 0.0128) [86].
Compared with placebo or active comparators,
liraglutide significantly improved markers of
b-cell function, including HOMA-B,
proinsulin–insulin ratio, and proinsulin–
C-peptide ratio [81–84]. Compared with
placebo, liraglutide significantly increases
first-phase insulin secretion and maximum
b-cell insulin secretory capacity [87].
Exenatide
Exenatide has been developed also as a
once-weekly formulation [exenatide
long-acting release (exenatide LAR)] that is
approved for treating T2DM [88–91]. In the
exenatide LAR formulation, the active peptide is
incorporated in poly-(D,L-lactic-co-glycolic acid)
matrix that provides controlled delivery [92],
allowing steady-state concentrations to be
achieved in 6–10 weeks and providing a
median half-life of 2 weeks [64, 90]. FPG levels
are improved after 2 weeks of treatment [89].
Studies have shown that exenatide once-weekly
and liraglutide provide better glycemic control
than exenatide twice-daily [85, 90, 91]. Two
randomized open-label studies found
significantly better glycemic control with the
once-weekly formulation compared to the
twice-daily formulation [90, 91]. The
once-weekly formulation reduced HbA1c by
1.6% after 24 weeks [91] and 1.9% after
30 weeks [90], compared to 0.9% after
24 weeks and 1.5% after 30 weeks with the
twice-daily formulation. Weight loss was
similar in all groups compared [90, 91].
In the DURATION-6 study, a 26-week,
open-label, randomized, parallel-group study
conducted at 105 sites in 19 countries, Buse
et al. compared the efficacy and safety of
liraglutide once-daily (1.8 mg) with exenatide
once-weekly (2 mg) in 912 patients with T2DM
[93]. They found that exenatide LAR and
liraglutide both improved glycemic control and
were associated with weight loss. Reductions in
HbA1c and weight loss were greater in the
liraglutide group than in the exenatide LAR
group, while adverse gastrointestinal events
and withdrawals due to adverse events were
more frequent in the liraglutide group. The
incidence of mild hypoglycemia was similar in
both groups, and nomajor hypoglycemic events
were reported. Patient-reported outcomes
improved in both groups.
Exenatide and liraglutide have provided
better glycemic control than other
anti-hyperglycemic drugs in comparative
studies. Exenatide LAR was more effective than
maximum-labeled doses of exenatide
twice-daily [90, 91], sitagliptin and
pioglitazone [88], and insulin glargine [89] in
patients treated with oral anti-hyperglycemic
drugs. Exenatide once-weekly reduced HbA1c to
a greater extent than sitagliptin in drug-naive
patients; it was not inferior to metformin, but
did not achieve non-inferiority to pioglitazone
[93]. The maximum-labeled dose of liraglutide
(1.8 mg) provided better glycemic control than
exenatide twice-daily [85], sitagliptin [95],
insulin glargine [83], and submaximal doses of
glimepiride [80] and rosiglitazone [81]. The
reductions in HbA1c noted for these
long-acting GLP-1 receptor agonists in
comparator-controlled trials were generally
greater than those of oral anti-hyperglycemic
drugs and basal insulin [81–83, 88–91, 93–95].
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It is important to note that, in the studies
mentioned above, liraglutide was administered
at the maximum dose of 1.8 mg and no studies
have compared exenatide LAR with liraglutide
twice-daily 1.2 mg or determined the relative
efficacies of the available injectable therapies for
glycemic control.
Scott et al. [96] performed a network
meta-analysis estimating the relative difference
in HbA1c for exenatide, exenatide LAR, insulin
glargine and liraglutide 1.2 and 1.8 mg
compared to placebo based on a combination
of direct and indirect clinical evidence. The
analysis suggests that exenatide LAR and both
doses of liraglutide are associated with clinically
important improvements in HbA1c, as shown
previously in clinical trials.
While the direct comparison identified a
significantly greater HbA1c reduction for
liraglutide 1.8 mg compared to exenatide LAR,
this network meta-analysis, which also includes
indirect data from additional trials, did not
identify important differences in HbA1c
reduction between the treatments [96].
Albiglutide
One of the newer long-acting GLP-1 RA is
albiglutide, which was approved by the FDA in
April 2014. It is a dimer of two copies of
30-amino acid fused to human albumin, and a
single amino acid substitution (glycine to
alanine), and achieves resistance to DPP-4
degradation [97]. The efficacy and safety of
albiglutide is demonstrated in the HARMONY
clinical trials. Data from these trials have shown
that albiglutide, in monotherapy or as add-on
to other diabetes therapies, lowered HbA1c
levels when compared with sitagliptin,
glimepiride, pioglitazone and insulin lispro
[98].
Comparison data between albiglutide and
lispro insulin in HARMONY-6 trial, in which it
met non-inferiority criteria, suggest that this
long-acting GLP-1 RA is a valid alternative to
lispro insulin in add-on basal insulin. Another
finding was the weight loss ability of albiglutide
compared to weight gain in patients treated
with lispro insulin [99].
In the HARMONY-7 clinical trial, it was
demonstrated that liraglutide at a dose of
0.6 mg titrated to 1.8 mg was more effective
than albiglutide (at a dose of 30 mg titrated to
50 mg), but gastrointestinal adverse event was
more frequent in liraglutide treatment [100].
Dulaglutide
Another once-weekly GLP-1 RA molecule
approved for the treatment of T2DM is
dulaglutide. It consists of a link between two
GLP-1 analog chains and immunoglobulin G
fragment. This structure confers a slower
absorption and reduced rate of renal clearance
[101]. The AWARD (Assessment of weekly
Administration of Dulaglutide) clinical trials
assessed the efficacy and safety of dulaglutide
as monotherapy and as add-on diabetes
therapy. This newer molecule is compared to
other hypoglycemic medications such as
short-acting exenatide, liraglutide, sitagliptin,
metformin and insulin lispro. The results have
shown a reduction of HbA1c raging from -0.78
to -1.51% [102]. In particular in the AWARD-6
trial, the efficacy of dulaglutide was comparable
to its primary competitor, liraglutide. The
reduction of HbA1c was -1.42% with
dulaglutide and -1.36% with liraglutide. A
significant greater reduction of weight loss was
obtained in liraglutide group, although both
molecules produced significant weight loss from
baseline [103]. Other clinical trials are
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investigating the efficacy of dulaglutide in
combination with insulin glargine and the
safety in patients with moderate and severe
chronic kidney disease.
CONCLUSION
Although most of the benefits of GLP-1 can be
exerted by both long-acting and short-acting
GLP-1 analogs, the short-acting preparation of
exenatide offers the additional benefit of greater
decelerating gastric emptying, which appears to
be the key factor driving the reduction of
postprandial glycemia [104]. Such additional
‘‘flattening’’ of postprandial glycemia seems to
complement the predominant reduction of
fasting glycemia achieved with a long-acting
insulin. In the study by Buse et al., the short
duration of exenatide action is illustrated by the
fact that glycemic excursions following lunch—
the meal that did not directly follow an
injection of exenatide—did not differ from
those with placebo [85].
It should be noted that exenatide twice-daily
(BID) and liraglutide, which were compared in
the LEAD-6 study, have different half-lives.
Exenatide has a half-life of 2–4 h, which is
similar to insulin aspart (3–5 h) or lispro (2–5 h);
whereas the half-life of liraglutide (13 h) is
comparable to that of detemir (14 h). As a
consequence, exenatide BID appears to be
more suitable for the treatment of patients
with predominantly postprandial hyper-
glycemia, whereas liraglutide as well as the
other long-acting GLP-1 RAs would be more
suitable for patients with predominantly fasting
hyperglycemia.
Interestingly, with regard to the effects on
gastric motility, glucose profiles and studies
with long-acting GLP-1 analogs have suggested
that tachyphylaxis—a weakening response over
time—may occur with increasing drug exposure
and concentrations. Comparatively, with the
fluctuating plasma levels of exenatide observed
with twice-daily injections, deceleration of
gastric emptying is fully maintained.
Thus, although most of the current
developments in the field of incretin mimetics
aim to increase half-lives and extend injection
intervals, these agents in combination with
basal insulin preparations may be a promising
area for short-acting compounds. Perhaps for
this reason, clinical trials of additional
short-acting incretin mimetics, such as
lixisenatide, are ongoing, with the aim of
combining these drugs with basal insulin. On
the other hand, the potential advantages of
long-acting GLP-1 analogs include a more
pronounced reduction of fasting glucose, less
frequent injections and lower rates of nausea
[85].
Clearly, glycemic control is not the only goal
of modern diabetes therapy. Insulin treatment
often increases body weight, whereas incretin
mimetics promote weight loss, which is
recommended for most patients with this
condition. Results from a pilot study [105],
suggest that the weight-lowering effect of
exenatide may predominate over the
insulin-induced weight gain. For this reason,
adding a GLP-1 analog may help to increase
quality of life during insulin therapy by
compensating for its tendency to cause weight
gain.
It should be emphasized that when added to
either sulfonylureas or insulin, GLP-1 RAs are
associated with increased risk of hypoglycemia.
Therefore, accurate titration of insulin doses by
glucose-self-monitoring is recommended when
such combinations are prescribed.
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